LOS ANGELES – (Oct. 28, 2014) – Each year, some 2,000 babies are born in the U.S. with a genetic heart condition, known as long QT syndrome. If not diagnosed in time, babies with long QT syndrome can die from a sudden arrhythmia, or irregular heartbeat.
If detected before the first symptom, long QT syndrome can be treated with medication – a beta-blocker –with great success. But detecting these electrical abnormalities in babies' hearts is difficult because there are no electrocardiogram (ECG) systems designed to record the electrical activities in the hearts of newborns.
A new device is in development, and the National Institutes of Health's National Heart, Lung, and Blood Institute recently awarded a grant to QT Medical, Inc. to continue its work on developing QTScreen, the first-ever ECG device that could be used by parents at home to screen their newborns for long QT syndrome.
QT Medical, Inc. is a spinoff company from Los Angeles Biomedical Research Institute (LA BioMed), and it will be conducting its research of QTScreen in collaboration with the nonprofit research institute.
"QTScreen has the potential to save the lives of infants whose heart problems might otherwise have gone undetected," said Ruey-Kang Chang, MD, an LA BioMed lead researcher, pediatric cardiologist and founder of QT Medical, Inc. "We designed the QTScreen to be easy to use, and we have proven that parents who had no prior training or experience could follow the simple instructions for using QTScreen to perform the tests for detecting long QT syndrome. QTScreen holds the promise of being the first ECG system that parents will be able to use at home to check their newborns for long QT syndrome."
QTScreen is smaller than a matchbox and features an array of electrodes positioned to fit on the tiny chests of newborns younger than a month old. With the first installment of about $295,000 from a nearly $2 million grant from the National Heart, Lung, and Blood Institute to develop the device, QT Medical will partner with LA BioMed to test the device by using it to screen 4,000 babies in Southern California for long QT syndrome.
Dr. Chang will be working with Henry J. Lin, MD, and Jerome I. Rotter, MD, at LA BioMed to conduct the clinical trial on the device. Other hospitals involved in the study will be St. Francis Medical Center and Little Company of Mary Hospital in Torrance.
About LA BioMed
Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and therapies for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit http://www.LABioMed.org